BioSpace News Archive

ValGenesis, Inc. announced that Continuus Pharmaceuticals, an end-to-end integrated continuous manufacturing company, successfully went live with the ValGenesis Validation Lifecycle Management System to efficiently manage validation processes across the company as 100% digital.

Cyclica Inc. and the National Research and Innovation Agency announce a partnership leveraging Cyclica’s AI-enabled drug discovery platform to drive innovation within Uruguay’s biotech ecosystem.

Neurolief, a medical neurotechnology innovator, announces the appointment of Anthony Borowicz as Chief Financial Officer.

The American Urological Association is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the inaugural Innovation Nexus Showcase.

VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient developed by Mitsui Chemicals Agro which has a different mode of action from existing vector control products.

Sensorion, a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the agenda for its R&D Day on Thursday 6 April 2023, at 8am EDT.

Photocure ASA announces its participation in the congress, and two abstract presentations at the European Association of Urology congress in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy in Bladder Cancer management.

Copperhead Chemical Company Inc., a subsidiary of PMC Group International, earned Northrop Grumman’s 2022 Strategic Excellence Award as part of their Supplier Excellence Awards.

Proteovant Therapeutics today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and on PVTX-405, an IKZF2 molecular glue, at the Targeted Protein Degradation Europe Conference, March 28-30 in London.

Ocean Biomedical, Inc., a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a “Buy” recommendation.